{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:10:21Z","timestamp":1784049021745,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05152-8","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:32:04Z","timestamp":1784046724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of RASopathy subtype on the early disease course of RASopathy-associated hypertrophic cardiomyopathy: clinical outcomes and genetic insights"],"prefix":"10.1038","author":[{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Guill\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilano","family":"Carcavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"D\u00edez-Sebasti\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Rikeros Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gambra-Arzoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Guti\u00e9rrez Larraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Deiros-Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"5152_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ajmg.c.32012","volume":"190","author":"M Tartaglia","year":"2022","unstructured":"Tartaglia, M., Aoki, Y. & Gelb, B. D. The molecular genetics of RASopathies: An update on novel disease genes and new disorders. Am. J. Med. Genet C. Semin Med. Genet. 190, 425\u2013439 (2022).","journal-title":"Am. J. Med. Genet C. Semin Med. Genet."},{"key":"5152_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01336-3","volume":"15","author":"S Zheng","year":"2022","unstructured":"Zheng, S., Huang, H., Ma, L. & Zhu, T. RASopathies due to de novo pathogenic variants: clinical features, genetic findings and outcomes in nine neonates born with congenital heart defects. BMC Med. Genomics 15, 184 (2022).","journal-title":"BMC Med. Genomics"},{"key":"5152_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/eurheartj\/ehy798","volume":"40","author":"G Norrish","year":"2019","unstructured":"Norrish, G. et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur. Heart J. 40, 986\u2013993 (2019).","journal-title":"Eur. Heart J."},{"key":"5152_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2023.01.012","volume":"81","author":"A Lynch","year":"2023","unstructured":"Lynch, A. et al. Risk of sudden death in patients with RASopathy hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 81, 1035\u20131045 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5152_CR5","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1002\/ehf2.13573","volume":"8","author":"G Norrish","year":"2021","unstructured":"Norrish, G. et al. Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. ESC Heart Fail 8, 5057\u20135067 (2021).","journal-title":"ESC Heart Fail"},{"key":"5152_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hfc.2021.07.004","volume":"18","author":"M Lioncino","year":"2022","unstructured":"Lioncino, M. et al. Hypertrophic cardiomyopathy in RASopathies: Diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail Clin. 18, 19\u201329 (2022).","journal-title":"Heart Fail Clin."},{"key":"5152_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ajmg.c.32014","volume":"190","author":"AB Delogu","year":"2022","unstructured":"Delogu, A. B. et al. The heart in RASopathies. Am. J. Med. Genet C. Semin Med Genet 190, 440\u2013451 (2022).","journal-title":"Am. J. Med. Genet C. Semin Med Genet"},{"key":"5152_CR8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ehf2.14637","volume":"11","author":"O Boleti","year":"2024","unstructured":"Boleti, O. et al. Natural history and outcomes in paediatric RASopathy-associated hypertrophic cardiomyopathy. ESC Heart Fail 11, 923\u2013936 (2024).","journal-title":"ESC Heart Fail"},{"key":"5152_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ajmg.a.32206","volume":"146A","author":"G Limongelli","year":"2008","unstructured":"Limongelli, G. et al. Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. Am. J. Med. Genet A 146A, 620\u2013628 (2008).","journal-title":"Am. J. Med. Genet A"},{"key":"5152_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ajmg.c.31765","volume":"184","author":"L Linglart","year":"2020","unstructured":"Linglart, L. & Gelb, B. D. Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment. Am. J. Med. Genet. C. Semin Med. Genet. 184, 73\u201380 (2020).","journal-title":"Am. J. Med. Genet. C. Semin Med. Genet."},{"key":"5152_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.recesp.2012.09.017","volume":"66","author":"A Carcavilla","year":"2013","unstructured":"Carcavilla, A. et al. LEOPARD syndrome: a variant of Noonan syndrome strongly associated with hypertrophic cardiomyopathy. Rev. Esp. Cardiol. (Engl. Ed.) 66, 350\u2013356 (2013).","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"5152_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.632293","volume":"9","author":"E Monda","year":"2021","unstructured":"Monda, E. et al. Hypertrophic cardiomyopathy in children: Pathophysiology, diagnosis, and treatment of non-sarcomeric causes. Front. Pediatr. 9, 632293 (2021).","journal-title":"Front. Pediatr."},{"key":"5152_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00018-007-6509-0","volume":"64","author":"T Edouard","year":"2007","unstructured":"Edouard, T. et al. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms? Cell Mol. Life Sci. 64, 1585\u20131590 (2007).","journal-title":"Cell Mol. Life Sci."},{"key":"5152_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ajmg.a.61434","volume":"182","author":"KW Gripp","year":"2020","unstructured":"Gripp, K. W. et al. The sixth international RASopathies symposium: Precision medicine-From promise to practice. Am. J. Med Genet. A 182, 597\u2013606 (2020).","journal-title":"Am. J. Med Genet. A"},{"key":"5152_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1151-0","volume":"14","author":"G Calcagni","year":"2019","unstructured":"Calcagni, G., Digilio, M. C., Marino, B. & Tartaglia, M. Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations. Orphanet J. Rare Dis. 14, 163 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"5152_CR16","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.febslet.2006.03.088","volume":"580","author":"N Hanna","year":"2006","unstructured":"Hanna, N. et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett. 580, 2477\u20132482 (2006).","journal-title":"FEBS Lett."},{"key":"5152_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-13","volume":"3","author":"A Sarkozy","year":"2008","unstructured":"Sarkozy, A., Digilio, M. C. & Dallapiccola, B. Leopard syndrome. Orphanet J. Rare Dis. 3, 13 (2008).","journal-title":"Orphanet J. Rare Dis."},{"key":"5152_CR18","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ajmg.a.38854","volume":"176","author":"MD Levin","year":"2018","unstructured":"Levin, M. D. et al. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients. Am. J. Med. Genet. A 176, 1711\u20131722 (2018).","journal-title":"Am. J. Med. Genet. A"},{"key":"5152_CR19","doi-asserted-by":"publisher","first-page":"e1149","DOI":"10.1542\/peds.2013-3189","volume":"134","author":"ME Pierpont","year":"2014","unstructured":"Pierpont, M. E. et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 134, e1149\u2013e1162 (2014).","journal-title":"Pediatrics"},{"key":"5152_CR20","doi-asserted-by":"crossref","unstructured":"Allanson, J. E. et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am. J. Med. Genet. C. Semin Med. Genet. 157C, 129\u2013135 (2011).","DOI":"10.1002\/ajmg.c.30295"},{"key":"5152_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ppedcard.2015.01.002","volume":"39","author":"BD Gelb","year":"2015","unstructured":"Gelb, B. D., Roberts, A. E. & Tartaglia, M. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog. Pediatr. Cardiol. 39, 13\u201319 (2015).","journal-title":"Prog. Pediatr. Cardiol."},{"key":"5152_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ajmg.10681","volume":"112","author":"MI Kavamura","year":"2002","unstructured":"Kavamura, M. I., Peres, C. A., Alchorne, M. M. A. & Brunoni, D. CFC index for the diagnosis of cardiofaciocutaneous syndrome. Am. J. Med. Genet. 112, 12\u201316 (2002).","journal-title":"Am. J. Med. Genet."},{"key":"5152_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/jmg.2007.054460","volume":"45","author":"CM Armour","year":"2008","unstructured":"Armour, C. M. & Allanson, J. E. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J. Med. Genet. 45, 249\u2013254 (2008).","journal-title":"J. Med. Genet."},{"key":"5152_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.425","volume":"41","author":"V Cordeddu","year":"2009","unstructured":"Cordeddu, V. et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat. Genet. 41, 1022\u20131026 (2009).","journal-title":"Nat. Genet."},{"key":"5152_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1442-200X.1996.tb03445.x","volume":"38","author":"T Nishikawa","year":"1996","unstructured":"Nishikawa, T. et al. Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr. Jpn 38, 91\u201398 (1996).","journal-title":"Acta Paediatr. Jpn"},{"key":"5152_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104372","volume":"65","author":"CM Wolf","year":"2022","unstructured":"Wolf, C. M. et al. Management of cardiac aspects in children with Noonan syndrome - results from a European clinical practice survey among paediatric cardiologists. Eur. J. Med. Genet. 65, 104372 (2022).","journal-title":"Eur. J. Med. Genet."},{"key":"5152_CR27","doi-asserted-by":"publisher","first-page":"S299","DOI":"10.21037\/cdt.2019.05.01","volume":"9","author":"E Kaltenecker","year":"2019","unstructured":"Kaltenecker, E. et al. Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy. Cardiovasc Diagn. Ther. 9, S299\u2013S309 (2019).","journal-title":"Cardiovasc Diagn. Ther."},{"key":"5152_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/ng2078","volume":"39","author":"MA Razzaque","year":"2007","unstructured":"Razzaque, M. A. et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat. Genet. 39, 1013\u20131017 (2007).","journal-title":"Nat. Genet."},{"key":"5152_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajhg.2013.05.021","volume":"93","author":"Y Aoki","year":"2013","unstructured":"Aoki, Y. et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS\/MAPK pathway syndrome. Am. J. Hum. Genet. 93, 173\u2013180 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"5152_CR30","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","volume":"73","author":"G Andelfinger","year":"2019","unstructured":"Andelfinger, G. et al. Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition. J. Am. Coll. Cardiol. 73, 2237\u20132239 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5152_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.103224","volume":"30","author":"TJ Millette","year":"2025","unstructured":"Millette, T. J., McCulloch, M. A., Yao, Q. & Hainstock, M. R. RVOT Stenting and Trametinib in an Infant With Noonan Syndrome, Pulmonary Stenosis, and Hypertrophic Cardiomyopathy. JACC Case Rep. 30, 103224 (2025).","journal-title":"JACC Case Rep."},{"key":"5152_CR32","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049107","volume":"15","author":"KE Hebron","year":"2022","unstructured":"Hebron, K. E., Hernandez, E. R. & Yohe, M. E. The RASopathies: from pathogenetics to therapeutics. Dis. Model Mech. 15, dmm049107 (2022).","journal-title":"Dis. Model Mech."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05152-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:32:05Z","timestamp":1784046725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05152-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":32,"alternative-id":["5152"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05152-8","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors confirm that patient consent forms have been obtained for this article.","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}